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ABSTRACT 
 
Effects of Different Molecular Weights of Hyaluronic 
Acids on Viscosities and Lysozyme- and Peroxidase-
related Enzymatic Activities 
 
Jihoon Kim, D.D.S., M.S.D. 
 
Program in Oral Medicine and Oral Diagnosis, Dept. of Dental 
Science, Graduate School, Seoul National University 
(Directed by Professor Hong-Seop Kho, D.D.S., M.S.D., Ph.D.) 
 
 
Objectives: Hyaluronic acid has been considered as a candidate molecule for saliva 
substitutes. To investigate influences of molecular-weight of hyaluronic acid on its 
rheological and biological properties, we examined viscosities of hyaluronic acids 
with different molecular-weights and their effects on lysozyme- and peroxidase-
related enzymatic activities both in solution and on hydroxyapatite surface. 
Methods: Four different-sized hyaluronic acids (10 kDa, 100 kDa, 1 MDa, and 2 
MDa), hen egg-white lysozyme (HEWL, 30 μg/mL), bovine lactoperoxidase 
(bLPO, 25 μg/mL), glucose oxidase-mediated peroxidase (GO-PO), and human 
whole saliva were used. Viscosity values for hyaluronic acids were measured by a 
cone-and-plate digital viscometer at six different concentrations (0.1, 0.2, 0.5, 1.0, 
2.0, and 5.0 mg/mL) and six different shear rates (11.3, 22.5, 45.0, 90.0, 225, and 
450 s-1). Enzymatic activities of lysozyme, peroxidase, and GO-PO were examined 
by hydrolysis of fluorescein-labelled Micrococcus lysodeikticus, oxidation of 
fluorogenic 2’,7’-dichlorofluorescein (LDCF) to fluorescing 2’,7’-
dichlorofluorescein (DCF), and production of oxidized o-dianisidine, respectively. 
Lysozyme and peroxidase activity were measured both in solution and on 
hydroxyapatite surface, and GO-PO activity was examined only in solution. For 
enzymatic activities, hyaluronic acids at 0.5 mg/mL were used. 
Results: The 100 kDa-hyaluronic acid at 5 mg/mL, 1 MDa at 0.5 mg/mL, and 2 
MDa at 0.2 mg/mL showed similar viscosity values to human whole saliva at the 
shear rates from 60 to 160 s-1. In solution assays, only 2 MDa-hyaluronic acid 
inhibited lysozyme activities in saliva significantly. In surface assays, high-
molecular-weight hyaluronic acids inhibited lysozyme and peroxidase activities 
and the inhibitory activities were more apparent on saliva than purified enzymes. 
GO-PO activities were not significantly affected by all the hyaluronic acids 
experimented. 
Conclusions: Hyaluronic acids of low-molecular-weight at high concentrations and 
high-molecular-weight at low concentrations showed similar viscosity values to 
human whole saliva, and inhibitory effects of hyaluronic acids on lysozyme and 
peroxidase activities were more significant in high-molecular-weight ones, on-
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Hyaluronic acid is one of the most common glycosaminoglycans in human body 
consisting of alternating D-glucuronic acid and N-acetyl-D-glucosamine units, 
which mostly exists in the vitreous humor of the eye, in the synovial fluid of 
articular joints, and in the extracellular matrix (Almond, 2007). The intrinsic 
biocompatibility of hyaluronic acid and its unique physical properties make it 
important for medical fields such as drug delivery (Luo et al., 2000), production of 
biomaterials (Collier et al., 2000), artificial tears (Doughty and Glavin, 2009), and 
substances for the symptomatic relief of osteoarthritis (Balazs, 1985; Moreland, 
2002). Hyaluronic acids exist in biological tissues and fluids as different molecular 
sizes and weights, and hyaluronic acids with different molecular weights are 
commercially available. Hyaluronic acid molecules may have different rheological 
and biological properties according to their molecular weights, which information 
is essential for the proper usage of hyaluronic acid in the development of 
biomaterials and medications. 
The presence of hyaluronic acid in human saliva has been reported, and salivary 
hyaluronic acid may contribute to the lubricating and healing properties of saliva, 
thereby assisting in protection of the oral mucosa (Pogrel et al., 1996, 2003). The 
anti-Candida activity of hyaluronic acid has also been reported (Kang et al., 2011; 
Sakai et al., 2007). Because of its viscoelastic properties, biocompatibility, and 
fungistatic activity, hyaluronic acid has been considered as a candidate molecule 
for saliva substitutes for patients with dry mouth whose susceptibility to candidiasis 
is increased. Interestingly, the relationship between the level of hyaluronic acid in 
saliva and the occurrence of dry mouth symptoms has been reported (Higuchi et al., 
2009). 
The development of effective saliva substitutes is the mimicry process of human 
saliva in the aspects of rheological and biological properties, which could be 
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influenced by molecular interactions. It has been reported that hyaluronic acid of a 
specific molecular weight showed similar viscosity values to human whole saliva 
at specific concentration ranges (Park et al., 2010). The influences of hyaluronic 
acid with a specific molecular weight on the enzymatic and candidacidal activities 
of lysozyme and peroxidase have also been demonstrated (Kang et al., 2011). 
Therefore, when hyaluronic acids of different molecular weights are involved, 
rheological and biological properties could be affected by their molecular weights. 
The formation of complex molecules between hyaluronic acid and salivary 
antimicrobial enzymes such as lysozyme and peroxidase have already been reported 
and ionic interaction has been suggested between hyaluronic acid and lysozyme or 
peroxidase (Green et al., 1990; Kang et al., 2011; Moss et al., 1997; Park et al., 
2010; Van Damme et al., 1991, 1994). Therefore, the amount of anionic charge that 
is directly related to the molecular weight of hyaluronic acid could affect the 
strength of ionic interaction and resulting enzymatic activities. Additionally, 
considering the possibility of molecular conformational changes on solid surfaces 
compared with in solution, the results of these interactions could be different on the 
tooth surface compared to in salivary fluid. Therefore, the purpose of this study was 
to investigate the influence of molecular weight of hyaluronic acid on its 
rheological and biological properties important for the development of oral health 
care products. Viscosity values of hyaluronic acids of four different molecular 
weights and their effects on lysozyme and peroxidase-related enzymatic activities 
both in solution and on hydroxyapatite surface were examined. 
 
 
II. REVIEW OF LITERATURE 
 




(1) Function of saliva 
Saliva is an essential oral fluid, which is a clear and slightly acidic mucoserous 
exocrine secretion from major and minor salivary glands (Humphrey and 
Williamson, 2001).Whole saliva contains glandular saliva, gingival crevicular fluid, 
desquamated oral epithelial cells, and microorganisms. Saliva has an important role 
in protecting, lubrication, buffering action, remineralization of teeth, antimicrobial 
activity, taste, and digestion (Mandel, 1987). By coating the oral mucosa with 
seromucous components, saliva protects and lubricates oral mucosal tissues against 
many irritants including proteolytic and hydrolytic enzymes from plaque and 
neutrophils, potential carcinogens from smoking, and desiccation from mouth 
breathing (de Almeida et al., 2008). The major components for lubricating effects 
are mucins which are secreted from mainly submandibular and sublingual salivary 
glands. Mucins are complex glycoprotein molecules that have the properties of low 
solubility, high viscosity, high elasticity, and strong adhesiveness (Humphrey and 
Williamson, 2001). Most of oral functions such as mastication, speech, and 
swallowing are helped by lubrication of mucins (Tabak, 1990). Buffering action of 
saliva is performed by bicarbonate, phosphate, urea, and amphoteric proteins and 
enzymes. Among them, bicarbonate is the most important buffering system, which 
diffuses into plaque and neutralizes acidic conditions. Remineralization of teeth 
could be done by salivary calcium and phosphate, which are maintained as a 
supersaturation state by salivary proteins. Salivary proteins, such as proline-rich 
proteins and statherins, have important roles to remineralize the enamel by 
stabilizing salivary calcium and phosphate, protecting the teeth from wear and 
mineral egress, and allowing the penetration of minerals for remineralization into 
the enamel. Saliva also has antimicrobial functions, which are performed by both 
immunologic components, such as secretory IgA, IgG, and IgM, and 
nonimmunologic components including mucins, peptides, and enzymes. The 
hypotonicity of saliva contributes to taste, which is also affected by salivary 
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proteins and gustin. Salivary amylases help digestion in early stage by breaking 
down starch, and salivary lubrication aid swallowing the food bolus. 
 
(2) Rheological properties of saliva 
Saliva is a non-Newtonian fluid, which has viscoelastic properties (Kho, 2014). 
Salivary glycoproteins, such as mucins, have a major role for viscoelasticity, mainly 
contributing to lubrication (Johansson et al., 1994). The viscosity of saliva may 
determine whether saliva could adhere to the oral mucosal surfaces in order to 
protect and lubricate the mucosal surfaces. Because the surfaces of oral cavity are 
in moving contact continuously, lubricating property of saliva is essential to protect 
the oral mucosa from irritation and damage (Schwarz, 1987). Salivary 
macromolecules contribute to forming a lubricant film on the oral tissues, which 
smoothens the oral surfaces, reduces the friction between food and mucosa, and 
makes the food bolus swallowed easily (Mandel, 1989). This film-coating property 
is mainly attributed to salivary mucins (Tabak et al., 1982). The wettability of saliva 
is also important property for retention and lubrication of oral removable appliances 
especially in xerostomic patients (Monsenego et al., 1989). 
 
(3) Biological properties of saliva 
Antimicrobial activities of saliva are performed by various components, such as 
lysozyme, peroxidase, mucins, lactoferrin, and immunoglobulins (Humphrey and 
Williamson, 2001). Among them, lysozyme and peroxidase are the most 
commercially used components for antibacterial or antifungal activities (Kho, 
2014). Lysozyme, which is derived from major and minor salivary glands, 
phagocytic cells, and gingival crevicular fluid, performs antimicrobial activities 
mainly by a muramidase activity and a cationic property (Laible and Germaine, 
1985). Furthermore, it has been reported that lysozyme might have antiviral 
properties, contributing to lysis of tumor cells (Lee-Huang et al., 1999, Sava et al., 
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1989). While most peroxidase activity in whole saliva is originated from salivary 
peroxidase secreted from major and minor salivary glands, some peroxidase activity 
is from myeloperoxidase of white blood cells exudated from gingival crevice. 
Peroxidase molecules perform antimicrobial activities by producing 
hypothiocyanite (OSCN-), resulting from oxidation of thiocyanate (SCN-) by 
hydrogen peroxide (H2O2) (Ashby, 2008). Glucose oxidase-mediated peroxidase 
(GO-PO) system, which does not exist in human saliva, is another peroxidase 
system, usually included in health care products to exert antimicrobial activities. 
For example, one GO-PO system which consists of bovine lactoperoxidase (bLPO), 
glucose oxidase, and SCN- exhibits candidacidal activities by utilizing glucose at a 
physiological glucose concentration in human saliva (Kho et al., 2012). Salivary 
mucins perform antimicrobial functions by controlling bacterial and fungal 
colonization via modulating adhesion of microbes (Humphrey and Williamson, 
2001). Lactoferrin, produced by intercalated ductal cells, adheres to salivary ferric 
irons, resulting in starvation of microorganisms which need ferric irons to survive 
(Mandel, 1976). Secretory IgA, which is the largest component among various 
immunologic contents in saliva, is produced by plasma cells in connective tissues, 
acting as an antibody to microbial antigens, aggregating bacteria to inhibit host 
tissue attachment, and neutralizing viruses (Dowd, 1999; McNabb, 1981). 
 
2. Dry mouth 
 
(1) Etiology, signs, and symptoms 
Xerostomia, usually defined as subjective discomfort of patients with dry mouth, 
has a variety of etiologies, including medications, Sjögren syndrome, radiotherapy 
in the head and neck region, and other systemic conditions (Guggenheimer and 
Moore, 2003). The most common etiological factor of dry mouth is taking various 
medications, and it has been reported that hundreds of medications contribute to 
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oral dryness of the patients (Scully, 2003). Sjögren syndrome is an autoimmune 
disease that characterized by lymphocytic infiltration of exocrine glands and 
epithelia in multiple sites, especially lacrimal and salivary glands, resulting in 
dryness of eye and oral cavity (Vitali et al., 2002). The radiation therapy of the head 
and neck cancers could injure major and minor salivary glands, resulting in decrease 
of salivary flow rate and changes in salivary composition (Shiboski et al., 2007) 
Patients with dry mouth often complain of difficulties in oral functions such as 
eating, swallowing, or speaking, as well as dry sensation of oral cavity, resulting in 
degradation of quality of life (Kho, 2014). Some patients with xerostomia might 
complain of burning sensation of tongue and oral mucosa, dysgeusia, or halitosis. 
Moreover, oral dryness could cause oral candidiasis or other infectious diseases and 
tend to increase the risk of dental caries or periodontitis.  
Typically, diagnostic evaluation of patients with dry mouth is performed by 
measuring salivary flow rates of whole saliva. The most common methods for 
measuring salivary flow rates are spitting or draining whole saliva into a test tube, 
and these methods have been identified to be reproducible and reliable (Navazesh, 
1993). Salivary flow rate could be measured at rest (unstimulated) or during 
chewing gum or wax (stimulated). Diagnostic criteria for hyposalivation is usually 
defined by a flow rate of unstimulated whole saliva (UWS) less than 0.1 mL/min, 
or that of stimulated whole saliva (SWS) less than 0.7 mL/min (von Bültzingslöwen 
et al., 2007). The patients with decreased flow rate of both UWS and SWS are 
considered as non-responders, while the patients with decrease flow rate of UWS 
only are regarded as responders (Sreebny and Broich, 1987). 
 
(2) Treatments 
 1) Intrinsic approach 
The intrinsic approach for the management of dry mouth patients is the 
prescription of parasympathomimetic sialogogue medications such as pilocarpine 
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and cevimeline, stimulating the residual capacity of hypofunctional salivary glands 
(Porter et al., 2004). It has been reported that these medications could help the 
patients with Sjögren syndrome (Al-Hashimi, 2005) and with a history of head and 
neck radiotherapy (Shiboski et al., 2007). However, sialogogues are not effective 
for all the patients with xerostomia, especially for non-responders, and have some 
degrees of side effects such as hypersalivation of other glands such as sweat glands 
and exacerbation of asthma, bronchitis, and cardiac symptoms. 
 
 2) Extrinsic approach 
For the patients who are not responsive to saliva stimulants or show side effects, 
extrinsic approach could be a help, which use artificial salivas or saliva substitutes. 
Most widely used saliva substitutes are sodium carboxymethylcellulose(CMC)- or 
animal mucin-based solutions, and these substitutes have been evaluated in terms 
of subjective improvements (Duxbury et al., 1989; Momm et al., 2005; Visch et al., 
1986; Vissink et al., 1983, 1987). Other saliva substitutes using other polymers or 
natural products have been also reported (Epstein et al., 2017; Morales-Bozo et al., 
2017; Ship et al., 2007). While these commercially used saliva substitutes may 
alleviate dry symptoms in some degrees, the effects are usually short-lasting and 
limited (Oh et al., 2008). In addition, electrostimulation has been suggested to be 
effective for xerostomic patients (Alajbeg et al., 2012; Strietzel et al., 2007). 
However, these stimulation therapies need more studies with longer-term and 
larger-size for clinical application. 
 
3. Hyaluronic acid 
 
 (1) Properties of hyaluronic acid 
Hyaluronic acid is a linear polymer consisting of alternating D-glucuronic acid 
and N-acetyl-D-glucosamine units, which belongs to the glycosaminoglycans 
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(Pogrel et al., 1996). Hyaluronic acid is abundant in the eye vitreous humor and in 
soft connective tissues (Almond, 2007), having important roles such as lubrication 
of joints and tissues (Arrich et al., 2005; Forsey et al., 2006; Moreland, 2003; Swann 
et al., 1974) or organizing framework of cartilage (Heinegård and Oldberg, 1989). 
The existence of hyaluronic acid in human whole saliva has been found, and 
salivary hyaluronic acid has been considered to contribute to wound healing and 
lubricating properties of saliva (Pogrel et al., 1996, 2003). Additionally, it has been 
suggested that hyaluronic acid also contributes to anti-Candida activity (Sakai et 
al., 2007) 
 
(2) Biomedical use of hyaluronic acid 
Due to intrinsic biocompatibility of hyaluronic acid, it has been used in a variety 
of biomedical fields. Since it was reported that hyaluronic acid injection into 
arthritic joints of horses reduced clinical symptoms effectively (Balazs and 
Denlinger, 1985), sodium hyaluronate preparations have been used to relieve the 
symptoms from osteoarthritis in medical and dental fields. Hyaluronic acid is also 
used during cataract surgery to facilitate surgical manipulation of ocular tissues and 
protect eye cells from damage (Almond, 2007). For this reason, it has been used in 
various medical surgeries for lubrication or hydration. The wound healing property 
of hyaluronic acid makes it useful in tissue engineering with ability to enhance 
keratinocyte proliferation and migration, as well as the angiogenesis in wound sites 
(Price et al., 2005). Also, hyaluronic acid derivatives have been used as diagnostic 
markers for intraperitoneal inflammation (Edelstam et al., 1994). 
 
(3) Hyaluronic acid as a base molecule as artificial saliva 
The viscoelastic properties and non-immunogeneity of hyaluronic acid make it 
possible to be recommended as a base molecule for saliva substitutes. To alleviate 
discomfort of the patients with xerostomia, most commonly used saliva substitutes 
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are CMC- or mucin-based mouth rinse solutions, and the efficacy of these solutions 
reducing subjective symptoms has been reported (Levine, 1993; Oh et al., 2008; 
Olsson and Axéll, 1991). However, most of previous studies have focused on the 
relief of subjective symptoms without evaluation of objective rheological or 
biological properties. In fact, rheological and biological properties of traditional 
saliva substitutes, such as mucin-based or CMC-based ones, are not so similar to 
those of human whole saliva. On the other hand, hyaluronic acid has been reported 
to have similar rheological properties to those of human whole saliva at a certain 
range of concentration (Park et al., 2010). The correlation of oral dryness symptom 
with decreased salivary levels of hyaluronic acid has also been reported (Higuchi 
et al., 2009), which imply that hyaluronic acid has an important role in lubrication 
and protection of oral mucosa and could be used as an effective saliva substitute. In 
addition, fungistatic activity of hyaluronic acid could be another advantage as a 
substance for oral health care products for patients with dry mouth, suggesting 
playing a role as an antimicrobial agent as well as a base molecule with viscoelastic 
property (Kang et al., 2011).   
 
4. Perspective in the development of artificial saliva 
 
To manage the patients with dry mouth, both intrinsic and extrinsic approaches 
can be used. However, the intrinsic method including sialogogue, such as 
pilocarpine and cevimeline, has several side effects and limited effectiveness due 
to short duration of efficacy and less satisfaction especially for the patients who are 
non-responders (Fox, 2004; Wiseman and Faulds, 1995). Therefore, development 
of new drugs with prolonged activity and less side effects is necessary. 
Development of effective saliva substitutes as an extrinsic approach is also 
important. It has been recommended that the addition of antimicrobial substances 
to base solutions rheologically similar to saliva might be more practical way to 
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develop artificial saliva (Kho, 2014). To achieve this goal, a thorough understanding 
of rheological properties of saliva and development of biologically beneficial 
antimicrobial substances insufficient in patients with dry mouth should be preceded. 
Molecular interactions of these substances with human saliva or saliva substitutes 
should also be evaluated. Based on the results of these objective researches, more 
effective saliva substitutes could be developed to reduce the discomfort of 
xerostomic patients. 
Another thing to be considered is how to provide artificial saliva continuously to 
the patients. A novel technique that could make artificial saliva remain for a long 
time in the oral cavity after single use is needed. Moreover, further studies for 
developing customized saliva substitutes that could satisfy the needs for individual 
patients or artificial saliva that could enhance salivary function even in patients 
without dry mouth might provide new directions for development of salivary 
researches. 
Although various polymers have been evaluated in terms of rheological and 
biological properties and molecular interactions, most studies have been limited to 
specific molecular weight at a certain range of concentrations (Cho et al., 2013; 
Kang et al., 2011; Kim et al., 2014; Park et al., 2007, 2010). Further studies on 
polymers with various molecular weights and a wide range of concentration are 
needed to determine better conditions. Therefore, to develop more effective saliva 
substitutes, additional studies on various candidate molecules for saliva substitutes 
are needed to find optimal conditions of both rheological and biological properties 
similar to human saliva without negative interactions, to alleviate subjective 
symptoms of patients with xerostomia. 
 
 




1. Participants and collection of saliva 
 
Saliva samples were collected from 4 healthy adults (2 males and 2 females, 28.5 
± 2.7 years) between 8 a.m. and 11 a.m. to minimize variability in salivary 
composition. All the participants had no medical histories for serious illnesses and 
medications affecting salivation at least for the recent three months. The oral 
hygiene and periodontal status of all participants were good. At the day of salivary 
collection, all participants refrained from eating, drinking, and tooth brushing for at 
least 1 h before the collection. UWS was collected by the spitting method. The 
collected saliva was placed in a chilled centrifuge tube in which 
phenylmethylsulfonyl fluoride (PMSF) was added immediately to a final 
concentration of 1.0 mM. The saliva sample was centrifuged at 3,500 x g for 15 
min at 4℃, and the clarified supernatant fluid was used immediately for assays. The 
research protocol was approved by the Institutional Review Board (IRB) of Seoul 
National University Dental Hospital (#CRI16010) and informed consent was 
obtained from all participants. 
 
2. Hyaluronic acid solution, lysozyme, peroxidase, and GO-PO 
 
Hyaluronic acids of four different molecular weights (10 kDa, 100 kDa, 1 MDa, 
and 2 MDa, Lifecore Biomedical, LLC, Chaska, MN, USA), which were 
solubilized with simulated salivary buffer (SSB, 0.021 M Na2HPO4/NaH2PO4, pH 
7.0, containing 36 mM NaCl and 0.96 mM CaCl2) (Bennick and Cannon, 1978), 
were used. Hyaluronic acids at six different concentrations (0.1, 0.2, 0.5, 1.0, 2.0, 
and 5.0 mg/mL) were used for the analysis of viscosity at each molecular weight. 
For the measurement of enzymatic activities, hyaluronic acids at the concentration 
of 0.5 mg/mL were used.  
Hen egg-white lysozyme (HEWL, final concentration of 30 μg/mL, Sigma–
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Aldrich Chemical Co., St. Louis, MO, USA) and bovine lactoperoxidase (bLPO, 
final concentration of 25 μg/mL, Sigma–Aldrich Chemical Co.) were used as 
sources of lysozyme and peroxidase, respectively. A glucose assay kit (Sigma-
Aldrich Chemical Co.) which included GO-PO reagent and o-dianisidine was used 
to analyze the effects of hyaluronic acid on the enzymatic activity of glucose 
oxidase-mediated peroxidase.  
 
3. Measurement of viscosity 
 
Viscosity was measured by a model LVT Wells-Brookfield cone-and-plate digital 
viscometer (Brookfield Engineering Laboratories, Stoughton, MA, USA). Shear 
rates were varied from 11.3 to 450 s-1 at six different speeds (11.3, 22.5, 45.0, 90.0, 
225, and 450 s-1). All measurements were performed at 37℃, and 0.5 mL volume 
of fluid was used in each test. The viscosity of each sample was measured ten times. 
The results of viscosity values of hyaluronic acids were compared to those of human 
whole saliva obtained from the previous study (Park et al., 2010). 
 
4. Measurement of enzymatic activity of lysozyme 
 
Lysozyme activity was measured by hydrolysis of fluorescein-labelled 
Micrococcus lysodeicticus (EnzCheck Lysozyme assay kit; Molecular Probes, 
Eugene, OR, USA). The preparation of substrate solution and incubation 
procedures was performed according to the manufacturer’s instructions. The 
enzymatic activity was measured by a fluorescence microplate reader (Synergy H1 
Hybrid Multi-Mode Microplate Reader, BioTek instruments Inc., Winooski, VT, 
USA) at an excitation of λ = 485 nm, and an emission of λ = 535 nm. 
 
(1) Influence of hyaluronic acid on lysozyme activity in solution phase 
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The effects of hyaluronic acids of four different molecular weights on HEWL 
and salivary lysozyme in solution were examined by incubating 500 μL of each 
hyaluronic acid with 500 μL of HEWL or clarified whole saliva for 30 min at room 
temperature (RT). The incubated mixture was placed in a suspension of fluorescein-
labelled M. lysodeikticus, and incubated buffer with HEWL or clarified whole saliva 
served as a control. An incubated mixture of hyaluronic acid with the buffer or an 
incubated buffer alone was used as a blank. 
 
(2) Influence of hyaluronic acid on lysozyme activity on surface phase 
To examine the influence of hyaluronic acid on the enzymatic activity of 
lysozyme adsorbed to hydroxyapatite surface, experiments were performed in two 
different ways. First, the effects of the hyaluronic acid which was pre-adsorbed on 
hydroxyapatite beads were examined on subsequent adsorption of lysozyme 
(surface assay I). Second, the effects of the hydroxyapatite-adsorbed lysozyme were 
observed after pre-incubation of hyaluronic acid with lysozyme (surface assay II). 
Ceramic hydroxyapatite beads (Macro-prep, HA type I) were obtained from Bio-
Rad (Hercules, CA, USA) and used as the surface assay. Ten milligrams of 
hydroxyapatite beads were used in each assay. 
In surface assay I, hydroxyapatite beads were coated with 300 μL of hyaluronic 
acid for 30 min at RT, and the coated beads were washed 5 times with the buffer. 
The hyaluronic acid-coated beads were incubated with 300 μL of HEWL or clarified 
whole saliva for 30 min at RT. Unbound HEWL or salivary molecules were 
removed by 5 washes. The beads were incubated with a suspension of fluorescein-
labelled M. lysodeikticus. Lysozyme activities of these samples were compared with 
those of the bare hydroxyapatite surface coated with HEWL or salivary lysozyme 
without hyaluronic acid coating. 
In surface assay II, 300 μL of hyaluronic acid was pre-incubated with 300 μL of 
HEWL or clarified whole saliva for 30 min at RT. After that, hydroxyapatite beads 
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were incubated with 600 μL of the hyaluronic acid-lysozyme mixture for 30 min at 
RT, and then washed 5 times with buffer to remove unbound molecules. Lysozyme 
activities of these samples were compared with those of the hydroxyapatite samples 
coated with the pre-incubated mixture of HEWL or clarified whole saliva with 
buffer. Equal amounts of hydroxyapatite beads incubated with hyaluronic acid, or 
an incubated buffer alone, were used as blanks. 
The experiments for measuring enzymatic activities of HEWL were performed 
eight times each in duplicate. The experiments for salivary lysozyme were also 
performed eight times in duplicate using pooled salivary samples from four 
participants. 
 
5. Measurement of enzymatic activity of peroxidase 
 
Peroxidase activity was determined by the method which was previously 
described by Proctor and Chan and Hannig et al. (Hannig et al., 2008, 2010a, 2010b; 
Proctor and Chan, 1994). In the presence of peroxidase and hydrogen peroxidase, 
fluorogenic 2’,7’-dichlorofluorescein (LDCF) is oxidized to fluorescent 
dichlorofluorescein (DCF). Stock solutions of the stable reagent 2’,7’-
dichlorofluorescein diacetate (LDADCF, Molecular Probes) were stored at -80℃ 
(5 x 10-5 M in absolute ethanol). The fluorogenic substrate LDCF was prepared 
freshly every day from LDADCF. One part of LDADCF solution was admixed to 
9 parts of 0.01 M sodium hydroxide, and incubated for 30 min. The reaction was 
stopped by addition of an equal amount of phosphate buffer (0.15 M, pH 6.0). The 
fluorescence of DCF was measured by a fluorescence microplate reader (Synergy 
H1 Hybrid Multi-Mode Microplate Reader, BioTek instruments Inc.) at an 
excitation of λ = 488 nm and an emission of λ = 530 nm. One unit of peroxidase 




(1) Influence of hyaluronic acid on peroxidase activity in solution phase 
The effects of hyaluronic acid on the enzymatic activity of bLPO or salivary 
peroxidase in solution were examined by incubating 500 μL of hyaluronic acid with 
500 μL of bLPO or clarified whole saliva for 30 min at RT. Four μL of the incubated 
mixture was added to 200 μL phosphate buffer (0.15 M, 1 mM KSCN, pH 6.0) and 
incubated for 10 min at 37℃. In the following, 20 μL of 2.2 mM hydrogen peroxide 
solution and 20 μL of the LDCF reagent were added. Following incubation for 4 
min, the reaction was stopped by adding 100 µl of 1 M sodium hydroxide. An 
incubated mixture of buffer with either bLPO or clarified whole saliva was used as 
a control, and an incubated mixture of hyaluronic acid with buffer or an incubated 
buffer alone was used as a blank. 
 
(2) Influence of hyaluronic acid on peroxidase activity in surface phase 
As the lysozyme assays, experiments on hydroxyapatite surfaces were performed 
in two different ways. In assay I, the effects of pre-adsorbed hyaluronic acid on 
subsequent absorption of peroxidase were examined. In assay II, hydroxyapatite-
adsorbed peroxidase activity was examined after pre-incubation of hyaluronic acid 
with peroxidase. The experiments were also performed eight times each in duplicate 
for measuring enzymatic activities of bLPO and salivary peroxidase. 
 
6. Measurement of enzymatic activity of GO-PO 
 
The GO-PO activity was measured by the glucose assay kit measuring oxidized 
o-dianisidine production. Oxidized o-dianisidine production, measured by OD at 
540 nm, reflected the enzymatic activity of GO-PO reagents. The GO-PO reagent 
in the glucose assay kit was divided into two parts, one dissolved in salivary 
simulated buffer and the other dissolved in the buffer containing hyaluronic acid, 
and pre-incubated for 30 min at RT. Enzymatic activity of the two different reagents 
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was measured using samples with known glucose concentrations (0.02, 0.04, and 
0.06 mg/mL). Experiments for enzymatic activity of glucose oxidase-mediated 
peroxidase were performed six times in duplicate. The glucose oxidase-mediated 




The Wilcoxon signed rank test was used to analyze statistical differences between 
the experimental groups with hyaluronic acid and the control groups without 





1. Viscosity of hyaluronic acid of different molecular weights 
 
The viscosity values for hyaluronic acids followed a pattern of non-Newtonian 
fluid at all four different molecular weights. As expected, hyaluronic acids of larger 
molecular weights or those at higher concentrations displayed higher viscosity 
values. Within a range of the concentrations experimented (0.1 - 5.0 mg/mL), 10 
kDa-hyaluronic acid showed the viscosity values from 0.73 to 0.88 cps (Fig. 1a), 
100 kDa-hyaluronic acid from 0.74 to 2.38 cps (Fig. 1b), 1 MDa-hyaluronic acid 
from 0.97 to 28.1 cps (Fig. 1c), and 2 MDa-hyaluronic acid from 1.36 to 28.1 cps 
(Fig. 1d) at a shear rate of 90 s-1. Hyaluronic acids of large molecular weights 
displayed increased viscoelastic properties, especially at a range of low shear rates. 
The 10 kDa-hyaluronic acid showed lower viscosity values than human whole 
saliva at all six concentrations used in these experiments (Fig. 2a). The 100 kDa-
hyaluronic acid at the concentration of 5 mg/mL displayed similar viscosity values 
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to those of SWS at lower shear rates (11.3, 22.5, and 45.0 s-1), while that at the 
concentration of 2 mg/mL showed the viscosity values similar to SWS at 225 s-1 
and UWS at 450 s-1 (Fig. 2b). 
The 1 MDa-hyaluronic acid at the concentration from 0.2 mg/mL to 1.0 mg/mL 
showed viscosity values similar to human whole saliva. At the concentration of 1.0 
mg/mL, 1 MDa-hyaluronic acid exhibited the similar viscosity values to SWS at 
the shear rates of 11.3 and 22.5 s-1, at the concentration of 0.5 mg/mL similar to 
SWS at the shear rate of 225 s-1 and similar to UWS at 450 s-1, and at the 
concentration of 0.2 mg/mL similar to SWS at 450 s-1 (Fig. 2c). 
The 2 MDa-hyaluronic acid at the concentration of 0.5 mg/mL or higher, 
displayed the viscosity values higher than human whole saliva at all six shear rates 
experimented. The 2 MDa-hyaluronic acid at the concentration of 0.2 mg/mL 
displayed the similar viscosity value to those for SWS at 45.0 s-1 and UWS at 225 
s-1, while that at the concentration of 0.1 mg/mL displayed the values similar to 
SWS at 225 s-1 and 450 s-1 (Fig. 2d).  
 
2. Effects of hyaluronic acid on enzymatic activity of lysozyme 
 
The effects of hyaluronic acid on the enzymatic activities of lysozyme were more 
significant on salivary lysozyme than HEWL, especially in high-molecular-weight 
ones, in both solution and surface assays. 
All hyaluronic acids at 0.5 mg/mL did not affect the enzymatic activities of 
HEWL in solution, but 2 MDa-hyaluronic acid inhibited the enzymatic activity of 
salivary lysozyme in solution phase significantly (P = 0.012). The 10 kDa-, 100 
kDa-, and 1 MDa-hyaluronic acids did not inhibit the enzymatic activities of 
salivary lysozyme (Table 1). 
While the enzymatic activities of both HEWL and salivary lysozyme on the 
hyaluronic acid-adsorbed hydroxyapatite surfaces (surface assay I) were not 
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affected at the molecular weights of 10 kDa, 100 kDa, and 1 MDa, the immobilized 
2 MDa-hyaluronic acid inhibited the enzymatic activities of HEWL (P = 0.017) and 
salivary lysozyme (P = 0.012) significantly (Table 2). 
When the pre-incubated mixture of hyaluronic acid and HEWL was adsorbed on 
the hydroxyapatite surfaces (surface assay II), the enzymatic activities of HEWL 
were not affected by 10 kDa- and 100 kDa-hyaluronic acids, but hyaluronic acids 
of 1 MDa (P = 0.017) and 2 MDa (P = 0.012) inhibited the enzymatic activities of 
HEWL significantly, especially in 2 MDa-hyaluronic acid decreasing more than 
20%. In the case of salivary lysozyme, 10 kDa-hyaluronic acid did not affect the 
enzymatic activity of HEWL, but hyaluronic acids of 100 kDa (P = 0.017), 1 MDa 
(P = 0.012), and 2 MDa (P = 0.012) inhibited the enzymatic activities of HEWL 
significantly. 
 
3. Effects of hyaluronic acid on enzymatic activity of peroxidase 
 
In the peroxidase assay, the results showed some differences from those of 
lysozyme assay. While it was similar to the lysozyme assay that the effects of 
hyaluronic acid on salivary peroxidase were more significant than those on the 
purified enzyme (bLPO), these effects were only observed on surface assay II. The 
hyaluronic acids of all molecular weights experimented did not affect the enzymatic 
activities of bLPO significantly in solution and on surface assay I, neither did the 
salivary peroxidase, even in large molecular weights such as 2 MDa (Table 3). 
The pre-incubated mixture of bLPO and 2 MDa-hyaluronic acid inhibited the 
enzymatic activity of bLPO significantly (P = 0.012) on hydroxyapatite surface 
(surface assay II), and pre-incubated salivary peroxidase with the hyaluronic acids 
of 1 MDa (P = 0.012) or 2 MDa (P = 0.017) decreased the salivary peroxidase 




4. Effects of hyaluronic acid on enzymatic activity of GO-PO 
 
All the hyaluronic acids of four different molecular weights at 0.5 mg/mL did not 
affect the enzymatic activities of GO-PO significantly at three different glucose 





With regard to the development of effective saliva substitutes, most studies have 
focused on subjective satisfaction of patients with dry mouth or xerostomia 
(Duxbury et al., 1989; Levine, 1993; Momm et al., 2005; Oh et al., 2008; Olsson 
and Axéll, 1991; Visch et al., 1986; Vissink et al., 1983, 1987). However, there have 
been few objective studies that investigated the rheological and biological 
properties of candidate substances for saliva substitutes. While saliva substitutes 
using CMC are still the most popular products, rheological and biological properties 
of CMC are not much similar to those of human whole saliva (Vissink et al., 1984). 
Previous studies using mucins of animal origin, mucilages of plant origin, and 
hyaluronic acid have showed that these substances have viscoelastic properties 
similar to human saliva, and have reported the results of their interactions with 
potential antimicrobial supplements (Kang et al., 2011; Kho et al., 2014; Park et al., 
2007, 2010; Vissink et al., 1984). Among these candidate substances, hyaluronic 
acid has an advantage as being one of the natural components present in human 
saliva. Hyaluronic acid of 1,630 kDa at the concentration of 0.5 mg/mL in SSB 
displayed similar viscosity values to those of SWS (Park et al., 2010). In the present 
study for further investigating the influences of molecular weight of hyaluronic acid, 
hyaluronic acids of four different molecular weights (10 kDa, 100 kDa, 1 MDa, and 
2 MDa) at six different concentrations (0.1, 0.2, 0.5, 1.0, 2.0, and 5.0 mg/mL) were 
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used to examine the viscosity values. The results showed that hyaluronic acids of 
low-molecular-weight except 10 kDa presented the viscosity values similar to 
human whole saliva at higher concentrations, while high-molecular-weight 
hyaluronic acids showed the similar viscosity values to those of human saliva at 
lower concentrations. The 100 kDa-hyaluronic acid at concentration of 5 mg/mL, 1 
MDa-one at 0.5 mg/mL, and the 2 MDa-one at 0.2 mg/mL showed viscosity values 
similar to those of SWS at a range of shear rates (from 60 to 160 s-1) which could 
reflect oral functions such as speaking or swallowing. These results supported the 
results of previous study that used 1,630 kDa-hyaluronic acid only (Park et al., 
2010). 
As salivary substitutes and human whole saliva might exist at the same time in 
the oral cavity, the interaction between molecules in human whole saliva and 
salivary substitutes should be considered to develop effective salivary substitutes. 
It has been reported that 1,630 kDa-hyaluronic acid did not affect the enzymatic 
activity of HEWL, salivary lysozyme, bLPO, and salivary peroxidase in solution 
phase (Park et al., 2010). In the present study using hyaluronic acids of different 
molecular weights at the concentration of 0.5 mg/mL, high-molecular-weight 
hyaluronic acids inhibited the lysozyme or peroxidase activities more than low-
molecular ones. Large-sized hyaluronic acids could interfere with diffusion of 
enzymes, which provide less opportunities to exert enzymatic activities. It has been 
reported that 1,630 kDa-hyaluronic acid inhibited candidacidal activities of 
lysozyme and peroxidase more at high concentration than at low concentration 
(Kang et al., 2011), suggesting that limitation of diffusion by concentrated 
hyaluronic acids could be a possible mechanism. The ionic interactions between 
hyaluronic acid and lysozyme and between hyaluronic acid and peroxidase have 
been reported (Green et al., 1990; Moss et al., 1997; Van Damme et al., 1991, 1994). 
The strength of ionic interaction could be affected by molecular weight of 
hyaluronic acid. However, enzymatic activity was not affected by these interactions 
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especially in the solution assays using purified ones in the present study. It has been 
reported that lysozyme activity of leucocytic lysosome was inhibited by hyaluronic 
acid even at low-molecular-weight, while peroxidase activity was not affected 
(Avila and Convit, 1975). The Ionic complex formation between hyaluronic acid 
and myeloperoxidase has been reported, although the complex did not affect the 
activity of myeloperoxidase significantly at low concentrations (Green et al., 1990). 
Therefore, the results of interactions between hyaluronic acid and antimicrobials 
enzymes could depend on the types of enzyme and experimental conditions. 
The results of present study showed that salivary lysozyme and peroxidase are 
more significantly inhibited by hyaluronic acids than purified enzymes both in 
solution and on hydroxyapatite surface except in solution assay of peroxidase. It 
could be explained that the influences of other molecules in saliva and formation of 
complex molecules could enhance the inhibitory effects of hyaluronic acids. It has 
been reported that mucinous component in saliva could interfere the diffusion of 
water molecules, which might explain more significant inhibitory effects of 
hyaluronic acids on salivary enzymes than purified enzymes (Lamy et al., 1990). 
Comparing solution assays with surface ones, it was observed that enzymatic 
activities were more affected by hyaluronic acid on hydroxyapatite surface than in 
solution. It could be assumed that the molecular conformations of hyaluronic acid 
or enzymes might be changed on the hydroxyapatite surface and these changes 
could have induced the different results between surface and solution assays. As 
surface assays, we performed the experiments in two different ways (surface assay 
I and surface assay II) to determine the influence of the reaction sequence, and the 
results were quite different. When pre-incubated hyaluronic acids with lysozyme or 
peroxidase were adsorbed to hydroxyapatite beads (surface assay II), the inhibitory 
effects were more significant than adsorption of hyaluronic acids to the beads before 
adsorption of enzymes (surface assay I). This might be due to increased adsorption 
of the ionic-complex molecules between hyaluronic acid and lysozyme or 
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peroxidase formed during pre-incubation to hydroxyapatite surface. 
The enzymatic activity of GO-PO was not inhibited by hyaluronic acids with all 
molecular weights experimented. It means that hyaluronic acids did not affect the 
activity of GO-PO even at high-molecular-weight in solution phase. Although 
enzymatic activity is not directly proportional to candidacidal activity, this finding 
is consistent with previous study which presented that hyaluronic acid inhibited 
candidacidal activities of glucose oxidase-mediated lactoperoxidase system less 
than those of lysozyme or peroxidase, suggesting that glucose oxidase-mediated 
lactoperoxidase system might be more advantageous as saliva substitutes for dry 
mouth patients in respect of antimicrobial properties (Cho et al., 2013). 
Based on the results of the present study, it should be discussed whether low-
molecular-weight at high concentrations or high-molecular-weight at low 
concentrations would be more beneficial for oral health. To solve the question, 
additional studies on both biological and rheological properties should be needed. 
In this study, we investigated the viscosity of hyaluronic acids in respect of 
interfacial rheology and effects on enzymatic activities. Further studies of other 
rheological properties including extensional variables such as surface tension and 
biocompatibility considering intraoral comfort should be considered. 
There were some limitations to extrapolate these in vitro results into the in vivo 
system. In the present study, the interactions between hyaluronic acids and 
antimicrobials were too simplified to evaluate the real interactions in human oral 
cavity, because there are various molecules which could also affect rheological and 
biological properties of hyaluronic acids and induce additional molecular 
interactions in the oral cavity.  
In conclusion, the present study investigated the effects of molecular weights of 
hyaluronic acid both on rheological (viscosity) and biological property (effects on 
enzymatic activity). High-molecular-weight hyaluronic acids at low concentration 
and low-molecular-weight at high concentration showed similar viscosity values to 
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human whole saliva at 60 - 160 s-1. Inhibitory effects of hyaluronic acids on 
lysozyme and peroxidase activities were more significant in high-molecular-weight 
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Table 1. Effects of hyaluronic acid with different molecular weights on enzymatic 






Lysozyme activity (Units/mL) 
P 
value Sample only 
With  
hyaluronic acid 
 Ratio (%) 
HEWL 
(n=8) 
10 kDa  2553.0  121.6  2509.0  108.9  98.4  4.3 0.263 
100 kDa 2595.6  69.3 2592.9  82.9 100.0  4.3 0.889 
1 MDa 2477.0  67.3  2451.0  123.5  98.9  4.5 0.575 




10 kDa   620.0  103.9   629.3  106.6 101.5  3.4 0.161 
100 kDa   629.5  108.7  626.7  90.8 100.1  4.1 0.674 
1 MDa  613.5  88.7  605.7  82.0  98.9  2.1 0.161 
2 MDa  651.0  87.6  601.5  81.5  92.4  2.3  0.012* 
HEWL, hen egg-white lysozyme 
MW, molecular weight 
Ratio (%), enzymatic activities of HEWL or human saliva with hyaluronic acids 
compared to those without hyaluronic acids 





Table 2. Effects of hyaluronic acid with different molecular weights on enzymatic 





















10 kDa 52.1  2.9 51.7  3.0  99.3  1.9 0.327 
100 kDa 52.2  4.2 51.7  3.7  99.2  1.7 0.208 
1 MDa 54.6  2.9 54.3  2.9  99.5  1.1 0.161 
2 MDa 54.3  3.6 53.7  3.3  99.0  1.2  0.017* 
Surface 
assay II 
10 kDa 52.4  2.4 52.6  2.4 100.3  2.3 0.726 
100 kDa 52.8  2.8 52.1  2.7  98.7  2.9 0.263 
1 MDa 54.4  6.7 49.9  6.4  92.0  7.4  0.017* 






10 kDa 35.1  5.9 34.9  5.6  99.7  2.7 0.779 
100 kDa 34.9  3.9 34.3  4.3  98.3  4.0 0.263 
1 MDa 32.7  4.1 31.9  5.0  97.1  3.8 0.069 
2 MDa 32.6  2.7 30.3  3.3  93.1  5.8  0.012* 
Surface 
assay II 
10 kDa 43.8  2.7 43.7  1.1 100.0  6.9 0.674 
100 kDa 44.1  4.6 41.3  5.4  93.6  5.3  0.017* 
1 MDa 36.1  7.8 33.1  7.0  91.6  2.2  0.012* 
2 MDa 38.4  6.5 29.5  6.0  76.6  7.3  0.012* 
HEWL, hen egg-white lysozyme 
MW, molecular weight 
Ratio (%), enzymatic activities of HEWL or human saliva with hyaluronic acids 
compared to those without hyaluronic acids 
Surface assay I, hyaluronic acids were adsorbed to hydroxyapatite beads first, and 
HEWL or human saliva was incubated on the hyaluronic acid-adsorbed beads next. 
Surface assay II, hyaluronic acids were pre-incubated with HEWL or human 
saliva, and the mixtures were adsorbed to hydroxyapatite beads. 





Table 3. Effects of hyaluronic acid with different molecular weights on enzymatic 






Peroxidase activity (Units/mL) 
P 
value Sample only 
With 
hyaluronic acid 
 Ratio (%) 
bLPO 
(n=8) 
10 kDa 7.14  1.00 6.95  0.80  97.8  5.7 0.327 
100 kDa 8.31  0.96 8.27  1.04  99.6  5.8 0.779 
1 MDa 8.17  0.71 8.06  0.86   99.0  11.8 0.889 




10 kDa 0.430  0.040 0.429  0.045  99.7  2.6 0.779 
100 kDa 0.439  0.028 0.434  0.030  99.0  3.0 0.310 
1 MDa 0.457  0.053 0.461  0.050 101.1  2.9 0.362 
2 MDa 0.459  0.030 0.459  0.032 100.1  1.9 0.888 
bLPO, bovine lactoperoxidase 
MW, molecular weight 
Ratio (%), enzymatic activities of bLPO or human saliva with hyaluronic acids 
compared to those without hyaluronic acids 





Table 4. Effects of hyaluronic acid with different molecular weights on enzymatic 





















10 kDa 5.87  0.11 5.90  0.08 100.7  2.0 0.528 
100 kDa 5.53  0.21 5.40  0.18  97.7  3.5 0.069 
1 MDa 6.14  0.40 6.09  0.37  99.2  1.6 0.236 
2 MDa 5.78  0.25 5.63  0.19  97.5  3.5 0.092 
Surface 
assay II 
10 kDa 4.97  0.31 4.97  0.29 100.0  2.0 0.944 
100 kDa 5.88  0.27 5.90  0.33 100.3  2.6 0.726 
1 MDa 5.22  0.22 5.14  0.27  98.5  3.4 0.182 






10 kDa 7.49  0.24 7.42  0.22  99.2  2.2 0.401 
100 kDa 7.50  0.54 7.50  0.56 100.0  2.1 0.889 
1 MDa 7.30  0.57 7.27  0.53  99.6  1.9 0.483 
2 MDa 7.14  0.25 7.00  0.29  98.1  4.1 0.093 
Surface 
assay II 
10 kDa 6.40  0.60 6.39  0.64  99.8  3.7 0.889 
100 kDa 6.84  0.41 6.69  0.50  97.8  2.7 0.068 
1 MDa 6.96  0.60 6.60  0.69  94.7  3.2 0.012* 
2 MDa 6.81  0.58 6.40  0.48  94.2  4.8 0.017* 
bLPO, bovine lactoperoxidase 
MW, molecular weight 
Ratio (%), enzymatic activities of bLPO or human saliva with hyaluronic acids 
compared to those without hyaluronic acids 
Surface assay I, hyaluronic acids were adsorbed to hydroxyapatite beads first, and 
bLPO or human saliva was absorbed to the hyaluronic acid-adsorbed beads next. 
Surface assay II, hyaluronic acids were pre-incubated with bLPO or human saliva, 
and the mixtures were adsorbed to hydroxyapatite beads. 





Table 5. Effects of hyaluronic acid with different molecular weights on enzymatic 







GO-PO activity (OD) 
P 




 Ratio (%) 
 10 kDa 
0.02 0.364  0.007 0.362  0.006 99.2  0.7 0.068 
0.04 0.703  0.010 0.700  0.009 99.6  0.7 0.207 
0.06 1.011  0.016 1.006  0.013 99.5  0.6 0.075 
100 kDa 
0.02 0.364  0.007 0.361  0.007 99.0  1.0 0.078 
0.04 0.703  0.010 0.697  0.009 99.1  0.8 0.068 
0.06 1.011  0.016 1.004  0.017 99.5  0.9 0.207 
  1 MDa 
0.02 0.364  0.007 0.362  0.007 99.3  1.1 0.207 
0.04 0.703  0.010 0.701  0.010 99.8  1.3 0.673 
0.06 1.011  0.016 1.010  0.019 99.9  1.3 0.833 
  2 MDa 
0.02 0.364  0.007 0.362  0.007 99.3  1.3 0.223 
0.04 0.703  0.010 0.702  0.012 99.9  1.9 0.833 
0.06 1.011  0.016 1.006  0.018 99.5  1.0 0.345 
GO-PO, glucose oxidase-mediated peroxidase 
MW, molecular weight 
Ratio (%), enzymatic activities of GO-PO with hyaluronic acids compared to those 
without hyaluronic acids 







Fig. 1. Viscosity values of hyaluronic acids at different concentrations. Viscosity 
measurements were performed at 6 different shear rates (11.3, 22.5, 45.0, 90.0, 225, 
and 450 s-1). (a) 10 kDa-hyaluronic acid, (b) 100 kDa-hyaluronic acid, (c) 1 MDa-
hyaluronic acid, (d) 2 MDa-hyaluronic acid 
 
Fig. 2. Viscosity values of hyaluronic acids compared with human whole saliva at 
different concentrations. Viscosity measurements were performed at 6 different 
shear rates (0.1, 0.2, 0.5, 1.0, 2.0, and 5.0 mg/mL). The viscosity values for 1 MDa-
hyaluronic acid at 2.0 and 5.0 mg/mL and 2 MDa-hyaluronic acid at 1.0, 2.0, and 
5.0 mg/mL were not shown for more detailed comparison. (a) 10 kDa-hyaluronic 
acid, (b) 100 kDa-hyaluronic acid, (c) 1 MDa-hyaluronic acid, (d) 2 MDa-
hyaluronic acid 
UWS, unstimulated whole saliva; SWS, stimulated whole saliva  
























































Hyaluronic acid의 분자량에 따른 차이가 점도 및 
Lysozyme과 Peroxidase 관련 효소 활성에  
미치는 영향 
 
김 지 훈 
서울대학교 대학원 치의과학과 구강내과·진단학 전공 
(지도교수 고 홍 섭) 
 
Hyaluronic acid는 glycosaminoglycan의 일종으로 인체에도 존재하
므로 생체 적합성이 뛰어나고 타액과 유사한 점탄성의 특성을 나타내므
로 타액대체물의 후보물질로 제시된 바 있다. 본 연구의 목적은 
hyaluronic acid의 분자량이 유동학적 및 생물학적 특성에 미치는 영향
을 조사하기 위한 것으로, 다양한 분자량의 hyaluronic acid의 점도를 
분석하고 분자량의 차이에 따라 hyaluronic acid가 lysozyme과 
peroxidase 관련 효소의 활성에 미치는 영향을 평가하는 것이다. 
실험에 사용된 hyaluronic acid는 네 가지 서로 다른 분자량의 상용
화된 hyaluronic acid (10 kDa, 100 kDa, 1 MDa 및 2 MDa)를 사용하
였고, 상용화된 효소로는 hen egg-white lysozyme (HEWL, 30 μ
g/mL), bovine lactoperoxidase (bLPO, 25 μg/mL)와 glucose 
oxidase-mediated peroxidase (GO-PO)를 사용하였으며, 연구대상자
로부터 인체 타액을 채취하여 타액 내 lysozyme과 peroxidase에 대한 
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분석도 시행하였다. Hyaluronic acid의 점도 측정을 위해 cone-and-
plate digital viscometer를 활용하여 6가지 농도 (0.1, 0.2, 0.5, 1.0, 
2.0 및 5.0 mg/mL)에서 전단 속도 (shear rate)를 11.3 s-1부터 450 
s-1까지 6단계로 증가시키면서 각각의 점도를 측정하였다. Lysozyme
의 효소 활성은 형광물질이 부착된 Micrococcus lysodeikticus가 가수
분해되는 정도를 측정하여 분석하였고, peroxidase의 효소 활성은 
fluorogenic 2 ’ ,7 ’ -dichlorofluorescein (LDCF)이 fluorescing 
2’,7’-dichlorofluorescein (DCF)으로 산화되는 정도를 측정하였으
며, GO-PO의 효소 활성은 산화된 o-dianisidine을 측정하여 분석하였
다. Lysozyme과 peroxidase의 활성은 용액 상태와 hydroxyapatite 
표면 상태에서 각각 측정하였고, GO-PO의 활성은 용액 상태에서만 측
정하였다. 효소 활성에 대한 영향을 측정하기 위해 0.5 mg/mL 농도의 
hyaluronic acid를 사용하였다. 
서로 다른 분자량의 hyaluronic acid를 이용하여 점도를 측정한 결과, 
연하 및 대화 시 발생하는 전단 속도인 60 s-1부터 160 s-1까지의 범
위에서 100 kDa-hyaluronic acid는 5 mg/mL의 농도에서, 1 MDa-
hyaluronic acid는 0.5 mg/mL의 농도에서, 2 MDa-hyaluronic acid는 
0.2 mg/mL의 농도에서 인체 타액과 비슷한 점도를 보였다. 효소 활성
에 대한 hyaluronic acid의 영향을 분석한 결과, 용액 상태에서는 2 
MDa-hyaluronic acid가 유일하게 타액 내 lysozyme 활성을 저해하였
고, 다른 분자량의 hyaluronic acid는 유의한 영향을 미치지 않았으며, 
또한 상용화된 효소들은 유의한 영향을 받지 않았다. 표면 상태에서는 
고분자량의 hyaluronic acid가 lysozyme과 peroxidase의 활성을 억제
함이 관찰되었고, 그 정도는 상용화된 효소보다 타액 내 효소들에서 더 
명확하게 관찰되었다. GO-PO의 활성은 본 실험에서 사용된 모든 분자
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량의 hyaluronic acid가 유의한 영향을 미치지 않았다. 
결론적으로, 고분자량의 hyaluronic acid는 저농도에서, 저분자량의 
hyaluronic acid는 고농도에서 인체 타액과 유사한 점도를 보였고, 
hyaluronic acid의 효소 활성 억제 효과는 저분자량보다는 고분자량에
서, 용액 상태보다는 표면 상태에서, 상용화된 효소보다는 타액 내 효
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